The Future of Healthcare: The Potential and Challenges of Virtual Wards

By Staff Writer

November 14, 2023

Embracing the Potential and Challenges of Virtual Wards

The National Institute for Health and Care Excellence (NICE) has recently recommended the exploration of virtual wards in healthcare. Virtual care is not a new concept. Recent health crises, like the COVID-19 pandemic, have propelled it into the spotlight. Virtual care, including telehealth and remote patient monitoring, has shown great promise in improving access to care, especially for those in remote or underserved areas. For example, early warning scores, such as NEWS2 and CRB65, are transforming the way we assess patients with suspected Acute Respiratory Infections (ARIs). These scores offer a promising avenue for clinical decision-making, especially in remote settings like call centres or primary care. They can be instrumental in determining care pathways, such as whether to send patients home, to ARI virtual wards, or to same day emergency care.

 

The Future of Remote Contact with NHS Services

Remote contact with National Health Service (NHS) services is gaining momentum. The guideline committee has made recommendations based on their expertise and experience, despite the fact that there is a lack of evidence on the use of remote assessments for those who have a suspicion that they have ARI. They are of the opinion that remote evaluations can be a beneficial tool for identifying persons who do not have major illnesses. However, they believe that an in-person assessment is essential for people who do have severe diseases.

The committee has also emphasised the significance of accessibility. Recognising that not everyone has equal access to or the capacity to use digital technology. However, they have emphasised the value of accessibility nonetheless. As a result, they have suggested that alternatives should be provided whenever they are required, and that the NHS has a responsibility to give reasonable adjustments to patients who have requirements in this regard.

As a result of the committee’s recommendations, antimicrobial stewardship is expected to be improved. This will lead to the beginning of a new era in healthcare. This will be accomplished by reducing the amount of antimicrobials that are prescribed without an in-person assessment.

Reference url

Recent Posts

DTC telehealth partnerships
           

DTC Telehealth Partnerships: Navigating Risks in Pharma’s Digital Expansion

🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?

Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.

Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.

#SyenzaNews #DigitalHealth #HealthEconomics #HealthcarePolicy

MAF Test breast cancer
       

MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Oncology

🌟 How can personalized medicine transform breast cancer treatment in Spain?

The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.

Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.

#SyenzaNews #precisionmedicine #HealthEconomics #innovation

ribociclib breast cancer guidance
           

NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patients in the NHS

🌟 Are we on the brink of transforming breast cancer treatment?

NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.

Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.

#SyenzaNews #oncology #costeffectiveness #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.